00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
22:18 , Aug 1, 2018 |  BC Extra  |  Company News

Management tracks: Hologic, Tricidia

Hologic Inc. (NASDAQ:HOLX) said Bob McMahon has departed as CFO to become CFO at Agilent Technologies Inc. (NYSE:A). The diagnostics company promoted Chief Accounting Officer Karleen Oberton to CFO. Metabolic acidosis play Tricida Inc. (NASDAQ:TCDA)...
17:50 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Obesity Mouse studies suggest inhibiting IDO could help treat obesity. In a mouse model of high-fat diet-induced obesity, systemic IDO knockout decreased white adipose tissue (WAT), liver and body weights, lipid levels in the...
18:23 , May 25, 2018 |  BC Week In Review  |  Company News

WHO to start treatment with Merck's Ebola vaccine

The World Health Organization began administering Ebola vaccine rVSV-ZEBOV (V920) from Merck & Co. Inc. (NYSE:MRK) on May 21 in two cities in the Democratic Republic of the Congo (DRC). Vaccination will be administered using...
23:03 , May 18, 2018 |  BC Extra  |  Politics & Policy

WHO: Congo may approve mAb Zmapp for Ebola outbreak

The Democratic Republic of the Congo is likely to approve the use of Zmapp “in the coming days” to treat patients affected by the country's Ebola outbreak, the World Health Organization said Friday. President Larry...
19:07 , May 18, 2018 |  BC Week In Review  |  Company News

Genentech terminates NewLink collaboration for IDO, TDO inhibitors

NewLink Genetics Corp. (NASDAQ:NLNK) said in an SEC filing that the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) terminated the remaining portion of a 2014 research collaboration that covered the development of next-generation indoleamine 2,3-dioxygenase...
23:01 , May 17, 2018 |  BC Extra  |  Company News

WHO to start treatment with Merck's Ebola vaccine

The World Health Organization said Thursday it plans to begin administering Ebola vaccine rVSV-ZEBOV (V920) in the Democratic Republic of the Congo "as soon as possible." WHO noted that 4,300 doses of the Merck &...
22:13 , May 14, 2018 |  BC Extra  |  Company News

DRC approves Merck vaccine for use in Ebola outbreak

The Democratic Republic of the Congo approved a protocol to use Ebola vaccine rVSV-ZEBOV (V920) from Merck & Co. Inc. (NYSE:MRK) on the heels of last week’s declaration by the World Health Organization of an...
18:09 , May 11, 2018 |  BC Week In Review  |  Company News

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced an Ebola virus outbreak in the...